Related Experiment Video
Updated: Mar 10, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
The effect of postoperative infection on survival in patients with glioblastoma
Yi-Ren Chen1, Beatrice Ugiliweneza2, Eric Burton3
1Department of Neurosurgery, Stanford University, Palo Alto, California.
Abstract:
OBJECTIVE Glioblastoma is a primary glial neoplasm with a median survival of approximately 1 year. There are anecdotal reports that postoperative infection may confer a survival advantage in patients with glioblastoma. However, only a few case reports in the literature, along with 2 retrospective cohort studies, show some potential link between infection and prolonged survival in patients with glioblastoma. The objective of this study was to evaluate the effect of postoperative infection in patients with glioblastoma using a large national database. METHODS The linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database was searched to identify patients 66 years of age and older with glioblastoma, with and without infection, from 1997 to 2010. The primary outcome was survival after diagnosis. The statistical analysis was performed with a graphical representation using Kaplan-Meier curves, univariate analysis with the log-rank test, and multivariate analysis with proportional hazards modeling. RESULTS A total of 3784 patients with glioblastoma were identified from the database, and from these, 369 (9.8%) had postoperative infection within 1 month of surgery. In patients with glioblastoma who had an infection within 1 month of surgery, there was no significant difference in survival (median 5 months) compared with patients with no infection (median 6 months; p = 0.17). The study also showed that older age, increased Gagne comorbidity score, and having diabetes may be negatively associated with survival. CONCLUSIONS Infection after craniotomy within 1 month was not associated with a survival benefit in patients with glioblastoma.
Insights
Postoperative infection in glioblastoma patients did not show a survival advantage. This large study found no significant difference in survival for glioblastoma patients with or without infection after surgery.
Area of Science:
- Neuro-oncology
- Surgical Oncology
- Infectious Disease Epidemiology
Background:
- Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis.
- Anecdotal reports suggest postoperative infections might improve survival in GBM patients.
- Existing literature includes limited case reports and small retrospective studies on this topic.
Purpose of the Study:
- To investigate the association between postoperative infection and survival in glioblastoma patients.
- To utilize a large national database for robust statistical analysis.
- To clarify the potential survival benefit of infection following glioblastoma surgery.
Main Methods:
- Utilized the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (1997-2010).
- Identified patients aged 66+ with glioblastoma, comparing those with and without postoperative infection within 1 month of surgery.
- Employed Kaplan-Meier curves, log-rank tests, and proportional hazards modeling for survival analysis.
Main Results:
- A total of 3784 glioblastoma patients were analyzed; 9.8% experienced postoperative infection.
- No significant difference in median survival was observed between infected (5 months) and non-infected (6 months) patients (p=0.17).
- Older age, higher comorbidity scores, and diabetes were negatively associated with survival.
Conclusions:
- Postoperative infection within one month of craniotomy is not associated with a survival benefit in glioblastoma patients.
- This finding challenges anecdotal reports and emphasizes the need for evidence-based conclusions.
- Further research may explore other factors influencing glioblastoma patient survival.
More Related Videos
13:37A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
Published on: March 12, 2014
05:45Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017